Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1. fázis

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

A legfontosabb adatok

Ki végzi
Yale University
Hol
New Haven (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
1. fázis
Résztvevők
4 fő vett részt
Kezdés
2026. márc. 26.
Várható befejezés
2027. febr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Semaglutide 1.0 mg
A regiszteradat frissítve
2026. szeptember 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)
  • Age 18 and older
  • Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years
  • Meet current DSM-5 criteria for Alcohol Use Disorder
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators
  • Read, comprehend, and write English at a sufficient level to complete study-related materials
  • For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation

Ki nem vehet részt

  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening
  • Is currently using other medications for weight loss or other GLP-1 receptor agonists
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device
  • History of malignant neoplasms within the past 5 years prior to screening
  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
  • Has a history of allergy or sensitivity to Semaglutide
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute
  • Has current uncontrolled hypertension
  • Has current uncontrolled Type I or Type II diabetes mellitus
  • Has active gallbladder disease
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder
  • Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months
  • Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use
  • Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol
  • Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
  • History or presence of chronic or recurrent pancreatitis
  • Is breast-feeding, pregnant, or not using a reliable form of birth control
  • Reports active suicidal or homicidal ideation

Helyszínek itt: Egyesült Államok

  • Yale School of MedicineNew Haven, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

A vizsgálat 2 csoportja

  • SemaglutideA vizsgált kezelés

    Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month. Participants will be on Semaglutide for three months total.

    Kezelés: Semaglutide 1.0 mg

  • Wait-list controlNincs vizsgálati kezelés, összehasonlításként

    Participants randomized to wait-list control will be followed for three months but no treatment will be administered. At the conclusion of the study, participants in the wait list control group will be offered a three-month behavioral intervention to treat Alcohol Use Disorder, although this is not required.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial
A regiszteradat frissítve
2026. szeptember 10.